Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2008 May;377(3):205-7.
doi: 10.1007/s00210-008-0280-0.

Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism?

Martin C Michel, Eric Fliers, Cornelis J F Van Noorden
Editorial

Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism?

Martin C Michel et al. Naunyn Schmiedebergs Arch Pharmacol. 2008 May.

Abstract

Inhibitors of the protease dipeptidyl peptidase IV (DPP-IV) are promising new drugs for the treatment of type 2 diabetes. They are thought to act by inhibiting the breakdown of glucagon-like peptide-1 and, thereby, selectively enhancing insulin release under conditions when it is physiologically required. These drugs are selective for DPP-IV, but the enzyme itself has a broad range of substrates other than glucagon-like peptide-1. Other high affinity substrates of DPP-IV including peptide YY may also play a role in the regulation of energy homeostasis. Moreover, DPP-IV is also known as CD26 and considered to be a moonlighting protein because it has a wide range of other functions unrelated to energy homeostasis, e.g. in immunity. The potential role of DPP-IV inhibition on substrates other than glucagon-like peptide-1 in diabetes patients remains to be elucidated.

PubMed Disclaimer

References

    1. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR (2002) Gut hormone PYY3–36 physiologically inhibits food intake. Nature 418:650–654 - DOI - PubMed
    1. Bischoff A, Michel MC (1998) Neuropeptide Y lowers blood glucose in anaesthetized rats via a Y5 receptor subtype. Endocrinol 139:3018–3021 - DOI - PubMed
    1. Boggiano MM, Chandler PC, Oswald KD, Rodgers RJ, Blundell JE, Ishii Y, Beattie AH, Holch P, Allison DB, Schindler M, Arndt K, Rudolf K, Mark M, Schoelch C, Joost HG, Klaus S, Thöne-Reineke C, Benoit SC, Seeley RJ, Beck-Sickinger AG, Koglin N, Raun K, Madsen K, Wulff BS, Stidsen CE, Birringer M, Kreuzer OJ, Deng XY, Whitcomb DC, Halem H, Tayloer J, Dong J, Datta R, Culler M, Ortmann S, Castaneda TR, Tschöp M (2005) PYY3–36 as an anti-obesity drug target. Obesity Rev 6:307–322 - DOI - PubMed
    1. Boonacker E, Van Noorden CJF (2003) The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 82:53–73 - DOI - PubMed
    1. Combettes M, Kargar C (2008) Newly approved and promising antidiabetic agents. Therapie 62:293–310 - PubMed

Publication types

MeSH terms